Rabbit B Cell Select Drives Clinical Breakthroughs in Cancer Treatment

ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), ImmunoPrecise Antibodies Ltd. (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today proudly announces the clinical progress achieved with rabbit monoclonal antibodies designed and developed using IPA's proprietary B Cell Select platform for the clinical-stage company, OncoResponse Inc. This achievement underscores IPA's leadership as a Contract Research Organization creating high-quality therapeutic antibodies, while pioneering work in the field of rabbit monoclonal antibody development. These antibodies are rapidly gaining recognition as a unique tool in therapies due to their distinctive properties, advancing into clinical trials aimed at improving patient outcomes.